Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional) | PAR 21 206

Opportunity Information: Apply for PAR 21 206

The NIH funding opportunity PAR-21-206, titled "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)," is designed to push promising scientific and engineering advances out of the lab and closer to real-world use. The central idea is to support academic and industry teams working together to translate discoveries into practical methods, tools, devices, or technology-enabled approaches that can improve how diseases are studied and how patients are assessed and cared for. Projects can focus on technologies that strengthen basic research capabilities for understanding disease mechanisms, or on applied research solutions that assess risk, detect disease earlier, prevent illness, improve diagnosis, enable or optimize treatment, and support ongoing disease management.

A major emphasis of the announcement is meeting evolving technology needs across the full continuum of research and care. That includes pre-clinical settings (for example, work that improves how therapies or biomarkers are evaluated before human use), clinical settings (tools that can be deployed in patient-facing environments), and non-clinical settings (such as community-based, field, or public health contexts). The FOA is broad in the sense that it is meant to align with the missions of the participating NIH institutes and centers, and it explicitly allows work in domestic or foreign settings, as long as the proposed technology and its intended impact fit those missions.

This opportunity uses the R01 mechanism, which generally supports well-developed, hypothesis-driven or milestone-driven research programs with clear technical goals and a plan for translation. The "Clinical Trial Optional" designation means applicants may propose studies that do not include a clinical trial, but they also have the flexibility to include a clinical trial component if it is appropriate for advancing the technology toward real-world use. In practice, that flexibility can accommodate a wide range of maturity levels, from advanced prototype validation and performance benchmarking to clinical feasibility or early effectiveness evaluation, provided the project is structured to produce tangible translational outcomes rather than remaining purely exploratory.

Eligibility is intentionally expansive to encourage diverse partnerships and to bring in organizations that can help technologies move from development into deployment. Eligible applicants include a wide range of U.S. governmental entities (state, county, city/township, and special district governments), tribal governments and tribal organizations (including federally recognized tribal governments and other tribal entities), public housing authorities/Indian housing authorities, K-12 independent school districts, and higher education institutions (public, state-controlled, and private). The FOA is also open to nonprofit organizations, both with and without 501(c)(3) status, and to for-profit organizations (including small businesses and other for-profits that are not small businesses). In addition, the announcement highlights "other eligible applicants" such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving institutions, Historically Black Colleges and Universities, Tribally Controlled Colleges and Universities, eligible federal agencies, faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and non-U.S. entities (foreign organizations). Taken together, this allows academic-industry collaborations to be structured in many ways, including multi-institution consortia and cross-sector partnerships that include community or regional implementation stakeholders.

From an administrative standpoint, the sponsor is the National Institutes of Health, the funding instrument is a grant, and the activity category is listed as education and health. The associated CFDA numbers are 93.394 and 93.395. The opportunity was created on March 25, 2021, and the listed original closing date is January 8, 2025. The award ceiling is shown as $499,000, which signals a budget constraint applicants should treat as a hard planning parameter when scoping aims, staffing, engineering builds, validation studies, and any regulatory or clinical activities. The posting does not specify an expected number of awards in the provided source data, so applicants typically need to assume competitive selection and craft a proposal that clearly articulates unmet need, technical innovation, feasibility, validation strategy, and a credible path to real-world adoption.

Overall, this FOA is best read as an invitation to build translation-ready technologies through genuine academic-industrial collaboration, with an emphasis on delivering new capabilities that can measurably improve research workflows or healthcare delivery. Strong applications are likely to be those that define a clear disease- or use-case-driven problem, show why existing tools fall short, present a realistic development and validation plan (often with engineering milestones and performance metrics), and demonstrate that the partnership has the combined expertise to move the technology toward meaningful use in pre-clinical, clinical, or field settings.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394, 93.395.
• This funding opportunity was created on 2021-03-25.
• Applicants must submit their applications by 2025-01-08. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $499,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 21 206

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: